INT2367

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1979
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 34
Total Number 35
Disease Relevance 8.46
Pain Relevance 8.62

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Sct)
Anatomy Link Frequency
pancreas 3
tendon 2
brain 2
nerve 2
forestomach 2
Sct (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Cholecystokinin 17 100.00 Very High Very High Very High
Enkephalin 13 100.00 Very High Very High Very High
Somatostatin 9 100.00 Very High Very High Very High
Pain 11 99.58 Very High Very High Very High
medulla 12 99.40 Very High Very High Very High
qutenza 28 99.16 Very High Very High Very High
antagonist 14 98.56 Very High Very High Very High
agonist 24 98.28 Very High Very High Very High
tetrodotoxin 8 98.16 Very High Very High Very High
peptic ulcer disease 1 97.88 Very High Very High Very High
Disease Link Frequency Relevance Heat
Sickle Cell Trait 5 100.00 Very High Very High Very High
Spherocytosis 5 100.00 Very High Very High Very High
Pain 8 99.58 Very High Very High Very High
Volume Depletion And Dehydration 1 99.44 Very High Very High Very High
Hepatotoxicity 5 99.40 Very High Very High Very High
Delirium 2 99.20 Very High Very High Very High
Pancreatitis 9 99.08 Very High Very High Very High
Diarrhoea 2 98.64 Very High Very High Very High
Mucositis 4 98.24 Very High Very High Very High
Cancer 4 97.96 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
At the same time, SCT is recognized as one of the most stressful treatments in modern cancer care, resulting in psychological distress, social isolation, and role changes.
SCT Binding (recognized) of associated with cancer
1) Confidence 0.42 Published 2010 Journal J Support Oncol Section Abstract Doc Link 20552923 Disease Relevance 0.92 Pain Relevance 0.22
Relief of suffering associated with SCT begins by understanding the patient experience and the SCT culture.
SCT Binding (associated) of
2) Confidence 0.42 Published 2010 Journal J Support Oncol Section Abstract Doc Link 20552923 Disease Relevance 0.55 Pain Relevance 0.14
Several treatments, including vagal ligation, vagotomy, perivagal application of capsaicin or colchicine, intravenous infusion of tetrodotoxin, and intraperitoneal injection of atropine, were performed to investigate their effects on secretin receptor binding to forestomach membranes.
secretin Binding (binding) of in forestomach associated with tetrodotoxin and qutenza
3) Confidence 0.37 Published 1999 Journal Am. J. Physiol. Section Abstract Doc Link 10198350 Disease Relevance 0 Pain Relevance 0.38
Specific binding of 125I-labeled secretin to forestomach membranes was significantly decreased (45%) by vagal ligation, vagotomy (50%), or perivagal colchicine treatment (40%).
secretin Binding (binding) of in forestomach
4) Confidence 0.37 Published 1999 Journal Am. J. Physiol. Section Abstract Doc Link 10198350 Disease Relevance 0 Pain Relevance 0.38
The aim was to see whether specific binding sites for AMY and/or for sCT present in these areas could be relevant to some of the biological activities of the two peptides.
sCT Binding (binding) of
5) Confidence 0.37 Published 2000 Journal Brain Res. Section Abstract Doc Link 10784109 Disease Relevance 0.05 Pain Relevance 0.18
It is therefore suggested that the central inhibitory activity of AMY on pain perception involves interaction with sCT receptors whereas the selective AMY binding sites subserve other (as yet unknown) functions.
sCT Binding (interaction) of associated with pain
6) Confidence 0.37 Published 2000 Journal Brain Res. Section Abstract Doc Link 10784109 Disease Relevance 0.17 Pain Relevance 0.38
Binding sites specific for [125I]AMY are present in the pons-medulla of rat brain as AMY, but not sCT, was able to displace radiolabeled AMY binding with an IC50 = 3.7+/-0.5x10(-10) M.
sCT Binding (binding) of in pons associated with medulla
7) Confidence 0.37 Published 2000 Journal Brain Res. Section Abstract Doc Link 10784109 Disease Relevance 0.07 Pain Relevance 0.23
Autoradiographic analyses of salmon calcitonin (sCT) binding in the rat mesencephalon revealed an exceptionally high concentration of receptors in the ventral and ventrolateral segments of the periaqueductal gray matter (PAG) extending along the entire rostral-caudal axis.
sCT Spec (analyses) Binding (binding) of in gray matter associated with urological neuroanatomy and central grey
8) Confidence 0.35 Published 1985 Journal Brain Res. Section Abstract Doc Link 2996694 Disease Relevance 0.24 Pain Relevance 0.25
Secretin injected i.p. may signal to the brain by interacting with secretin receptors on vagal afferent as well as on AP neurons outside the blood-brain barrier.
secretin Binding (interacting) of in brain
9) Confidence 0.34 Published 2004 Journal Neuroscience Section Abstract Doc Link 15450360 Disease Relevance 0.09 Pain Relevance 0.33
Both aluminum and magnesium silicate also extensively bound (> 82%) to other peptide hormones including Met-enkephalin, somatostatin, and secretin, but did not bind their degradation products.
secretin Binding (bound) of associated with somatostatin and enkephalin
10) Confidence 0.34 Published 1992 Journal Anal. Biochem. Section Abstract Doc Link 1456442 Disease Relevance 0 Pain Relevance 0.26
On the contrary, specific binding of 125I-secretin was not affected by perivagal capsaicin treatment, intravenous infusion of tetrodotoxin, or intraperitoneal injection of atropine.
125I-secretin Binding (binding) of associated with tetrodotoxin and qutenza
11) Confidence 0.32 Published 1999 Journal Am. J. Physiol. Section Abstract Doc Link 10198350 Disease Relevance 0 Pain Relevance 0.46
We conclude that chronic treatment with secretin plus caerulein exerts a trophic effect on the pancreas associated with increased maximal protein output to cholecystokinin and increased maximal bicarbonate output to secretin.
secretin Binding (associated) of in pancreas associated with cholecystokinin
12) Confidence 0.32 Published 1979 Journal Gastroenterology Section Abstract Doc Link 422007 Disease Relevance 0.16 Pain Relevance 0.22
We conclude that chronic treatment with secretin plus caerulein exerts a trophic effect on the pancreas associated with increased maximal protein output to cholecystokinin and increased maximal bicarbonate output to secretin.
secretin Binding (treatment) of in pancreas associated with cholecystokinin
13) Confidence 0.32 Published 1979 Journal Gastroenterology Section Abstract Doc Link 422007 Disease Relevance 0.16 Pain Relevance 0.23
In contrast, binding of [125I]sCT was displaced by both sCT and AMY, although with different potencies, the IC50 for sCT being 1+/-0.1x10(-11) M, and for AMY, 1.8+/-0.08x10(-7) M.
sCT Binding (binding) of
14) Confidence 0.32 Published 2000 Journal Brain Res. Section Abstract Doc Link 10784109 Disease Relevance 0.08 Pain Relevance 0.24
Iodinated secretin retained intrinsic biological activity in that it was as effective but 2.5-times less potent than native secretin in its ability to bind to pancreatic acini and to increase cellular cAMP.
secretin Binding (bind) of
15) Confidence 0.32 Published 1983 Journal Am. J. Physiol. Section Abstract Doc Link 6309017 Disease Relevance 0.07 Pain Relevance 0.16
Secretin (20 pmol . kg-1 . h-1 iv) or 0.03 N HCl (4.32 ml/h id) was infused in conscious rats with gastric cannulas or anesthetized rats with ligation of the pylorus, respectively.
Secretin Binding (ligation) of in pylorus
16) Confidence 0.31 Published 1998 Journal Am. J. Physiol. Section Abstract Doc Link 9655680 Disease Relevance 0 Pain Relevance 0.43
For a given agonist, however, a 40-fold higher concentration was required for half-maximal inhibition of binding of 125I-secretin than was required to produce a half-maximal increase in cellular cAMP.
secretin Binding (binding) of associated with agonist
17) Confidence 0.29 Published 1983 Journal Am. J. Physiol. Section Abstract Doc Link 6309017 Disease Relevance 0.15 Pain Relevance 0.54
Binding of 125I-secretin was inhibited by secretin, vasoactive intestinal peptide, PHI, and Gila monster venom but not by glucagon, gastric inhibitory polypeptide, cholecystokinin, caerulein, gastrin, bovine pancreatic polypeptide, somatostatin, neurotensin, leucine-enkephalin, methionine-enkephalin, carbachol, bombesin, litorin, eledoisin, physalaemin, or substance P.
secretin Binding (Binding) of associated with somatostatin, enkephalin, cholecystokinin, monsters and substance p
18) Confidence 0.29 Published 1983 Journal Am. J. Physiol. Section Abstract Doc Link 6309017 Disease Relevance 0.16 Pain Relevance 0.38
Scatchard analysis of binding of 125I-secretin indicated that each pancreatic acinar cell has approximately 93,000 binding sites, half of which are occupied by 11 nM iodinated secretin.
secretin Binding (binding) of in acinar cell
19) Confidence 0.29 Published 1983 Journal Am. J. Physiol. Section Abstract Doc Link 6309017 Disease Relevance 0.07 Pain Relevance 0.23
With agonists (secretin, vasoactive intestinal peptide, PHI, or Gila monster venom), as well as antagonists (C-terminal fragments of secretin), there was a close correlation between their relative potencies for inhibiting binding of 125I-secretin and their relative potencies for increasing cAMP (agonists) or inhibiting the secretin-induced increase in cAMP (antagonists).
secretin Binding (binding) of associated with antagonist, agonist and monsters
20) Confidence 0.29 Published 1983 Journal Am. J. Physiol. Section Abstract Doc Link 6309017 Disease Relevance 0.18 Pain Relevance 0.58

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox